Product Description
a pill that contains a mix of select bacteria found to be associated with better checkpoint inhibitor response
Mechanisms of Action: Microbiome Modulator
Novel Mechanism: Yes
Modality: Microbiome
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Parker Institute for Cancer Immunotherapy
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Melanoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03817125 |
MCGRAW | P1 |
Completed |
Melanoma |
2022-03-04 |
12% |
2022-06-10 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |